# Vietnam Pharmaceutical Landscape Framework

## Regulatory Environment

**MOH Structure**:
- Ministry of Health → Drug Administration of Vietnam (DAV) oversees registration

**Approval Process**:
- Typically 18–24 months
- Delays common due to dossier verification

**Pricing & Reimbursement**:
- Governed by MOH and Social Health Insurance (SHI)
- Tiered by product category

**Recent Changes (2023–2025)**:
- Draft reforms to accelerate approval timelines
- Allow parallel importation
- Modernize reimbursement mechanisms

## Healthcare System

**Public vs. Private**:
- ~70% public healthcare expenditure
- Private sector growing rapidly

**Hospital Structure**:
- Central (tier 1) hospitals
- Provincial hospitals
- District hospitals
- Commune hospitals
- Public hospitals dominate procurement

**Pharmacy Landscape**:
- 60,000+ outlets
- Dominated by small independents
- Rising modern chains (Pharmacity, Long Châu)

**Pricing Dynamics**:
- Controlled markups in hospitals
- Competitive retail pricing

## Market Structure

**Top Domestic Firms**:
- Traphaco
- DHG Pharma
- Imexpharm
- OPC

**Major Multinationals**:
- GSK
- Sanofi
- Pfizer
- Novartis
- Roche
- MSD

**Market Size**:
- ~$7–8 billion (2024 estimate)
- Growing 8–10% CAGR

**Key Therapeutic Categories**:
- Anti-infectives
- Cardiovascular
- Diabetes
- Oncology
- Vaccines

## Distribution Channels

**Hospital Procurement**:
- Dominant through tenders and distributor relationships

**Pharmacy Distribution**:
- Growing fast via modern retail and e-commerce platforms

**Government Tenders**:
- Centralized under MOH and provincial health departments

**Drug Stores**:
- OTC-driven
- Crucial for vaccines and chronic therapies
